High Evidence
Research Overview
Liraglutide Research for Obesity
An evidence-based overview of research examining Liraglutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Liraglutide 3.0mg (Saxenda) is FDA-approved for chronic weight management. SCALE trials demonstrated 8% average weight loss at 56 weeks, with 63% achieving clinically significant (>5%) weight loss. Also approved for adolescents 12-17 years.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Liraglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.